Skip to main content
Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · IEX Real-Time Price · USD
5.51
-0.30 (-5.16%)
May 17, 2024, 4:00 PM EDT - Market closed

Foghorn Therapeutics Revenue

Foghorn Therapeutics had revenue of $33.90M in the twelve months ending March 31, 2024, with 64.41% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $5.05M, a -4.88% decrease year-over-year. In the year 2023, Foghorn Therapeutics had annual revenue of $34.16M with 77.63% growth.

Revenue (ttm)
$33.90M
Revenue Growth
+64.41%
P/S Ratio
6.96
Revenue / Employee
$292,207
Employees
116
Market Cap
235.92M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202334.16M14.93M77.63%
Dec 31, 202219.23M17.91M1,357.77%
Dec 31, 20211.32M889.00K206.74%
Dec 31, 2020430.00K--
Dec 31, 20190--
Dec 31, 20180--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AngioDynamics 324.01M
Coherus BioSciences 301.87M
Akebia Therapeutics 187.23M
G1 Therapeutics 84.04M
OptimizeRx 78.21M
NeuroPace 69.07M
908 Devices 50.73M
uniQure 19.00M
Revenue Rankings

FHTX News

More News